Effects of PPAR-γ knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 6, 2007, Pages 346-354

  Pandey, Nihar R ^a   Benkirane, Karim ^a   Amiri, Farhad ^a   Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Glucose metabolism; GLUT 4; GSK 3 ; Hypertension; PPAR ; siRNA

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; ROSIGLITAZONE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERTENSION; INSULIN SENSITIVITY; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GENE SILENCING; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HYPERTENSION; INSULIN; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34347214016     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31804654d7     Document Type: Article

References (38)

1. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597-H1602.
2. Rosen OM. After insulin binds. Science. 1987;237:1452-1458.
3. Bevan P. Insulin signalling. J Cell Sci. 2001;114:1429-1430.
4. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001;86:972-979.
5. Schiffrin EL, Amiri F, Benkirane K, et al. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003;42:664-668.
6. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
7. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
8. Loviscach M, Rehman N, Carter L, et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia. 2000;43:304-311.
9. Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518-524.
10. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
11. Benkirane K, Amiri F, Diep QN, et al. PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol. 2006;290:H390-H397.
12. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249-254.
13. Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45-51.
14. Sharma V, McNeill JH. The etiology of hypertension in the metabolic syndrome part three: the regulation and dysregulation of blood pressure. Curr Vasc Pharmacol. 2006;4:321-348.
15. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes. 1993;42:8-11.
16. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-267.
17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
18. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 1996;93:1809-1817.
19. Tordjman K, Bernal-Mizrachi C, Zemany L, et al. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 2001;107:1025-1034.
20. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
21. Takehara N, Kawabe J, Aizawa Y, et al. High glucose attenuates insulin-induced mitogen-activated protein kinase phosphatase-1 (MKP-1) expression in vascular smooth muscle cells. Biochim Biophys Acta. 2000;1497:244-252.
22. Fukuda N, Hu WY, Teng J, et al. Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 2002;163:229-239.
23. Karlsson HK, Hallsten K, Bjornholm M, et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes. 2005;54:1459-1467.
24. Miyazaki Y, He H, Mandarino LJ, et al. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes. 2003;52:1943-1950.
25. Wu Y, Ouyang JP, Wu K, et al. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. Br J Pharmacol. 2005;146:234-243.
26. Bento JL, Palmer ND, Mychaleckyj JC, et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes. 2004;53:3007-3012.
27. Xiong C, Mou Y, Zhang J, et al. Impaired expression of PPARγ protein contributes to the exaggerated growth of vascular smooth muscle cells in spontaneously hypertensive rats. Life Sci. 2005;77:3037-3048.
28. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
29. Freedman BD, Lee EJ, Park Y, et al. A dominant negative peroxisome proliferator-activated receptor-γ knock-in mouse exhibits features of the metabolic syndrome. J Biol Chem. 2005;280:17118-17125.
30. Iglarz M, Touyz RM, Viel EC, et al. Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineral-ocorticoid-dependent hypertension. Hypertension. 2003;42:737-743.
31. 2 is a ligand for the adipocyte determination factor PPARγ. Cell. 1995;83:803-812.
32. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptorγ (PPARγ). J Biol Chem. 1995;270:12953-12956.
33. Barak Y, Nelson MC, Ong ES, et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-595.
34. Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005;289:H813-H822.
35. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 1997;100:2158-2169.
36. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000;106:165-169.
37. Kramer DK, Al-Khalili L, Perrini S, et al. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes. 2005;54:1157-1163.
38. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277:25226-25232.